Welcome to our dedicated page for Roivant Sciences Ltd. Common Shares news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences Ltd. Common Shares stock.
Roivant Sciences Ltd. (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to revolutionize healthcare by accelerating the development and commercialization of crucial medicines. With a mission to bring innovative treatments to market swiftly, Roivant builds nimble subsidiaries known as 'Vants' to optimize efficiency in pharma R&D and commercialization.
Roivant’s diversified pipeline includes VTAMA®, a novel topical approved for psoriasis and in development for atopic dermatitis, along with other promising drug candidates such as batoclimab, IMVT-1402, and brepocitinib. These candidates are being developed for various autoimmune and inflammatory conditions, including non-infectious uveitis, dermatomyositis, and other IgG-mediated autoimmune indications.
The company’s strategy involves forming strategic partnerships with leading academic institutions and biopharmaceutical companies to enhance its therapeutic portfolio. Notably, collaborations with Takeda, Priovant, and Immunovant have bolstered its drug development capabilities.
Recent advancements include significant progress in clinical trials, such as positive Phase 2 results for brepocitinib in non-infectious uveitis and the successful launch of VTAMA for psoriasis. Additionally, Roivant's acquisition of Telavant and robust financial performance underscore its growth trajectory and commitment to addressing unmet medical needs.
Roivant’s innovative approach also extends to incubating discovery-stage companies and health technology startups, ensuring a continuous pipeline of next-generation therapies. The company’s forward-thinking model focuses on areas with high societal medical needs, aiming to deliver impactful solutions to patients globally.
For more detailed and up-to-date information on Roivant Sciences Ltd., visit their official website.
Aruvant Sciences presented clinical data on its gene therapy ARU-1801 for severe sickle cell disease (SCD) at the ASGCT annual meeting on May 16, 2022. The data indicates ARU-1801 significantly reduces vaso-occlusive events and hospitalization days for patients. This therapy uniquely employs reduced intensity conditioning, setting it apart from other treatments. In the ongoing MOMENTUM trial, participants showed durable responses with four out of five experiencing complete resolution of severe events. These findings may enhance patient quality of life and lower healthcare costs.
Roivant Sciences has appointed Dr. Srini Ramanathan as Chief Development Officer, bringing over 20 years of drug development experience from Horizon Therapeutics. Dr. Ramanathan has a proven track record in advancing clinical portfolios and has contributed to multiple drug approvals in virology and oncology. Roivant's subsidiaries, Proteovant Therapeutics and VantAI, have also established collaborations with Blueprint Medicines, Janssen, and Boehringer Ingelheim, focusing on innovative drug development with potential aggregate milestone payments exceeding $1 billion.
Dermavant Sciences announced positive results from the Phase 3 PSOARING 3 long-term extension study for tapinarof cream 1% in treating plaque psoriasis. Over 52 weeks, tapinarof showed durable improvements in efficacy, quality of life, and tolerability without irritation. The study demonstrated significant enhancements in key metrics such as % body surface area (%BSA) affected and Psoriasis Area and Severity Index (PASI). Dermavant aims for FDA approval, with a target action date set for Q2 2022, which could position tapinarof as a novel therapeutic option for psoriasis patients.
Roivant Sciences (Nasdaq: ROIV) announced that CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on March 16, 2022, at 1:15 p.m. ET. A live webcast will be accessible on the Roivant Investor Relations website. Roivant aims to enhance healthcare delivery by addressing inefficiencies and developing transformative medicines through its innovative Roivant platform. For updates, visit www.roivant.com.
Genevant Sciences and Arbutus Biopharma have filed a lawsuit against Moderna for patent infringement related to key patents in nucleic acid delivery technology used in the manufacture of their COVID-19 vaccine, mRNA-1273. The patents involved include U.S. Patent Nos. 8,058,069, 8,492,359, and others. Importantly, Genevant and Arbutus are not seeking to halt the sale or distribution of mRNA-1273. The lawsuit follows a recent legal victory for Genevant and Arbutus, where a court upheld the patentability of their technologies.
Genevant emphasizes the significance of lipid nanoparticle technology in mRNA delivery.
Roivant Sciences has launched Hemavant, a subsidiary that secured a licensing agreement with Eisai Co., Ltd. for RVT-2001, targeting anemia in myelodysplastic syndromes. Dermavant is preparing for the anticipated FDA decision on tapinarof for psoriasis, with favorable Phase 3 trial results in atopic dermatitis. Genevant's patent portfolio was upheld against Moderna, and Immunovant aligned with the FDA for a pivotal trial in myasthenia gravis. As of December 31, 2021, Roivant reported $2.2 billion in cash, with a net loss of $306.1 million for the quarter.
Roivant Sciences (NASDAQ: ROIV) will host a live conference call and webcast on February 14, 2022, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. The call can be accessed at +1-844-224-1923 for domestic and +1-214-989-7105 for international calls. Roivant will also present at three major healthcare conferences this February and March, including the SVB Leerink Global Healthcare Conference and Cowen Healthcare Conference.
Roivant Sciences (Nasdaq: ROIV) announced CEO Matt Gline will present at two conferences: the B. Riley Securities Virtual Oncology Conference on January 27, 2022, at 12:30 p.m. ET, and the SVB Leerink Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. Live webcasts will be available on the Roivant investor website, with archived recordings accessible for 30 days. Roivant aims to enhance healthcare delivery and develop transformative medicines through its innovative platform.
TandemAI has appointed Albert Pan, Ph.D., as Chief Technology Officer and Lanny Sun as Chairman of the Board of Directors. Dr. Pan brings over 20 years of experience in molecular simulation and drug discovery, previously at D.E. Shaw Research. Sun is a seasoned executive with a strong biotechnology background, co-founding Silicon Therapeutics, which was acquired by Roivant Sciences in 2021. TandemAI recently completed a $25 million funding round to enhance its recruitment and expand drug discovery operations utilizing AI-based tools.
Roivant Sciences (Nasdaq: ROIV) announced a licensing agreement with Eisai Co., Ltd. for global rights to RVT-2001, aimed at treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS). RVT-2001, an orally available small molecule, has been tested in over 80 human subjects. Roivant will expand its clinical trial for RVT-2001 this year. Details will be discussed during a presentation at the J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET.
FAQ
What is the current stock price of Roivant Sciences Ltd. Common Shares (ROIV)?
What is the market cap of Roivant Sciences Ltd. Common Shares (ROIV)?
What is Roivant Sciences Ltd. known for?
What are the key products in Roivant's pipeline?
What is the goal of Roivant’s business model?
Who are some of Roivant’s strategic partners?
What recent achievements has Roivant made?
How does Roivant's 'Vant' model work?
What is VTAMA® used for?
How does Roivant contribute to innovation in drug development?
Why is Roivant’s approach significant?
Where can I find more information about Roivant?
